Neurolixis Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including Parkinson's disease, Rett syndrome, depression and schizophrenia. Neurolixis advances the clinical development of in-licensed clinical-phase drugs as well as identifying novel chemical entities. Neurolixis actively pursues collaborations and has been awarded grants by Parkinson's UK, the Michael J. Fox Foundation, Parkinson's UK, the International Rett Syndrome Foundation and the Rett Syndrome Research Trust.